Cargando...
Safety of Extended Interval Tobramycin in Cystic Fibrosis Patients Less Than 6 Years Old
OBJECTIVES: The primary objective of this study was to assess the nephrotoxicity and ototoxicity risks of extended interval tobramycin in cystic fibrosis (CF) patients who are <6 years old. A secondary objective included analyzing pharmacokinetic parameters in this age group. METHODS: A retrospec...
Gardado en:
| Publicado en: | J Pediatr Pharmacol Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Pediatric Pharmacy Advocacy Group
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916444/ https://ncbi.nlm.nih.gov/pubmed/29720918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5863/1551-6776-23.2.152 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|